 HOLON, Israel, June 8, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo nivolumab in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. 